![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
Background: Pharmacokinetic interactions can make necessary anti-epileptic medication (AED) changes hazardous for children with epilepsy. We report the utility of a dosing algorithm designed to maintain stable trough lamotrigine (LTG) concentrations during conversion from valproate (VPA) to LTG monotherapy in adolescents aged 16–20 years.
Methods: Patients were enrolled into the study if they required a change in their AED regimen due to lack of efficacy or intolerable side effects. Conversion to LTG monotherapy took place in a four part treatment algorithm. Lamotrigine was escalated according to a target dose of 200 mg/day over 8‐weeks. Valproate was withdrawn over a period of 2–6 weeks, depending on the initial dose. Lamotrigine dose was further escalated to 500 mg/day and continued for four weeks as monotherapy. Trough serum concentrations of LTG were measured during each phase of the trial.
Results: Twelve of 16 patients completed the study. After the LTG escalation to 200 mg/day, mean trough serum concentrations of 8.0 μg/mL did not differ significantly from the 9.5 μg/mL after VPA withdrawal or the 9.2 μg/mL after 4 weeks of monotherapy at 500 mg/day. Adverse events led to premature discontinuation for one subject. Two subjects withdrew due to worsening seizures during LTG monotherapy possibly due to non-compliance. Limitations of the trial include the open label design and small sample size of the sub-analysis.
Conclusion: In adolescent patients, this algorithm produces stable LTG serum concentrations with favorable tolerability during a transition from VPA to LTG monotherapy.
* Some of the data described in this manuscript were presented at the 2004 annual meeting of the Child Neurology Society (October 13–16, 2004 Ottawa, Canada)
* Some of the data described in this manuscript were presented at the 2004 annual meeting of the Child Neurology Society (October 13–16, 2004 Ottawa, Canada)
Notes
* Some of the data described in this manuscript were presented at the 2004 annual meeting of the Child Neurology Society (October 13–16, 2004 Ottawa, Canada)